Targeted elimination of intracellular reactive oxygen species using nanoparticle-like chitosan- superoxide dismutase conjugate for treatment of monoiodoacetate-induced osteoarthritis

Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems

“… [ 169 ] O-HTCC SOD Slow release In vitro & vivo Chondrocytes; Rats O-HTCC-SOD was nontoxic to chondrocytes and had more long-acting and intracellular protection effects on chondrocytes against MIA-induced oxidative damage; O-HTCC-conjugated SOD significantly prolonged half-life and residence in rat joint cavity, and improved bioavailability compared with unmodified SOD; Intra-articular injection of O-HTCC-SOD significantly attenuated mechanical allodynia in MIA-induced osteoarthritis rats, dramatically suppressed gross morphological and histological lesions of articular cartilage, and greatly enhanced in vivo antioxidant capacity and anti-inflammatory effect. [ 170 ] PPNP Dex ROS-responsive In vitro & vivo RAW264.7; Mice The drug could efficiently inhibit the ROS and nitric oxide production in lipopolysaccharide-activated RAW264.7 macrophages and modulate macrophages M2 polarization at a much lower concentration than free drug dexamethasone; The monosodium iodoacetate-induced OA mice treated with this drug was very similar with the normal mice with the evaluation of body weight and scores including clinical arthritis scores, claw circumference, and kinematics scores. [ 171 ] PAMAM/ C11 peptide/ CH6 aptamer - Bone targeting In vitro & vivo Osteoblastic; Rats Nano-carrier could successfully accumulate in the targeted cells, mineralized areas and tissues.…”

“…In some instances, cartilage targeting originates in the basic material of the PNPs. 163–166 In addition, dextran sulfate used to target macrophages, 168 HAP-1 peptide used to target synovial, 169 O-HTCC (O-(2-hydroxyl) propyl-3trimethyl ammonium chitosan chloride) and polyphenol–poloxamer used to target ROS, 170 , 171 C11 peptide (the C-terminal region of rh174) used to target bone, 172 PNPs have also been developed to target the specific microenvironment of OA joint.…”

New insights in osteoarthritis diagnosis and treatment: Nano‐strategies for an improved disease management

“…The former show good biocompatibility and easy surface modification though its low water solubility and poor targeting efficiency may impair its successful application. Chitosan-based NPs were successfully tested in a monoiodoacetate OA in vivo model (Gao et al, 2020). In particular, IA administration of cationic functionalized chitosan chemically conjugated with superoxide dismutase (SOD) produced a decrease in articular cartilage damage and mechanical allodynia as well as anti-inflammatory effects.…”

Vascular Repair by Grafting Based on Magnetic Nanoparticles

“…ROS is both a signaling molecule and an inflammatory mediator, which is central to the progression of many inflammatory diseases [ 145 ]. Under normal physiological conditions, ROS of the body is maintained at a low level of dynamic balance and participates in many important physiological processes, such as controlling the inflammatory reaction, killing toxic and harmful substances or tumor cells, promoting leukocyte phagocytosis, responding to growth factor stimulation, participating in the synthesis of biological macromolecules such as prothrombin and collagen, and participating in cell differentiation, proliferation, apoptosis, migration, and other cellular processes [ 146 , 147 ]. For vascular structures, once the body is pathologically damaged, the level of ROS will increase, which can trigger a series of inflammatory reactions, resulting in apoptosis or death of cells, thereby aggravating the damage of vascular structures.…”